Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) shares reached a new 52-week high during trading on Monday. The company traded as high as $61.51 and last traded at $61.51, with a volume of 503,200 shares changing hands. The stock had previously closed at $59.37.
Analyst Ratings Changes
A number of analysts recently commented on the company. Royal Bank Of Canada assumed coverage on Roche in a research note on Tuesday, September 8th. They issued an “outperform” rating for the company. Oddo Bhf raised shares of Roche to an “outperform” rating in a research report on Tuesday, October 20th. Zacks Research upgraded shares of Roche from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. UBS Group cut shares of Roche from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 2nd. Finally, HSBC reaffirmed a “hold” rating on shares of Roche in a research note on Thursday, September 10th. Eight research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.
Read Our Latest Research Report on RHHBY
Roche Trading Down 0.7%
The stock’s 50-day moving average price is $56.13 and its two-hundred day moving average price is $53.95. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.23 and a quick ratio of 0.95.
Institutional Investors Weigh In On Roche
Several hedge funds have recently bought and sold shares of RHHBY. S&CO Inc. lifted its holdings in shares of Roche by 163.0% during the first quarter. S&CO Inc. now owns 140,551 shares of the company’s stock valued at $6,880,000 after purchasing an additional 87,107 shares during the last quarter. Opal Capital LLC bought a new position in Roche during the 1st quarter valued at approximately $4,448,000. First Command Advisory Services Inc. raised its stake in Roche by 188.7% during the third quarter. First Command Advisory Services Inc. now owns 37,694 shares of the company’s stock valued at $1,956,000 after buying an additional 24,639 shares during the last quarter. GAMMA Investing LLC raised its stake in Roche by 15.3% during the third quarter. GAMMA Investing LLC now owns 33,458 shares of the company’s stock valued at $1,736,000 after buying an additional 4,443 shares during the last quarter. Finally, Associated Banc Corp bought a new stake in Roche in the third quarter worth $1,740,000.
Roche Company Profile
Roche is a Swiss healthcare company with two main businesses: pharmaceuticals and diagnostics. Founded in Basel in 1896, the company develops and commercializes medicines and provides diagnostic tests, instruments, and digital health solutions. Its pharmaceutical research and products span areas including oncology, immunology, neuroscience, ophthalmology, and infectious diseases. Its diagnostics business serves clinical laboratories, hospitals, healthcare providers, and patients with tools used to detect and monitor a range of medical conditions.
Recommended Stories
- Five stocks we like better than Roche
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.
